Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Obstetrics and Gynecology Reports
Published in: Current Obstetrics and Gynecology Reports 1/2014

01-03-2014 | Management of Gestational Trophoblastic Diseases (A Cheung, Section Editor)

Management Options of Gestational Trophoblastic Disease

Authors: Ross S. Berkowitz, Donald P. Goldstein, Neil S. Horowitz

Published in: Current Obstetrics and Gynecology Reports | Issue 1/2014

Login to get access

Abstract

During the past year, studies have advanced the understanding and management of gestational trophoblastic diseases. Molar pregnancy is now diagnosed earlier in gestation across the globe due to increasingly availability of hCG measurement and pelvic ultrasound. Earlier diagnosis reduces the presence of classic signs and symptoms but does not affect the frequency of postmolar gestational trophoblastic neoplasia (GTN). Molar pregnancy is known to be more common at the extremes of reproductive age, and studies have advanced our understanding of the natural history of molar pregnancy in adolescents and women in their 40s. Studies also have improved administration of chemotherapy. A prospective, randomized trial showed that pulse actinomycin D induced higher complete remission rates than weekly methotrexate in low-risk GTN. Investigations also have indicated the proper amount of consolidation chemotherapy in low-risk GTN and the value of low-dose induction chemotherapy in patients with a high disease burden. However, important work remains to be done.
Literature
1.
Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009;112:654–2.PubMedCrossRef
2.
Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic diseases. Lancet. 2010;376(9742):717–29.PubMedCrossRef
3.
Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011;204(1):11–8.PubMedCrossRef
4.
Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol. 1978;131(6):665–71.PubMed
5.
Szulman AE, Surti U. The syndromes of hydatidiform mole. II. Morphologic evolution of the complete and partial mole. Am J Obstet Gynecol. 1978;132(1):20–7.PubMed
6.
Montes M et al. Prevalence and significance of implantation site trophoblast atypia in hydatidiform moles and in spontaneous abortions. Am J Clin Pathol. 1996;105:411–6.PubMed
7.
Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531–9.PubMedCrossRef
8.
9.
10.
Yamashita K et al. Human lymphocyte antigen expression in hydatidiform mole: androgenesis following fertilization by a haploid sperm. Am J Obstet Gynecol. 1979;135(5):597–600.PubMed
11.
Hancock BW et al. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole: incidence and outcome. J Reprod Med. 2006;51:764–6.PubMed
12.
Feltmate CM et al. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J Reprod Med. 2006;51:902–6.PubMed
13.
Soto-Wright V et al. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol. 1995;86:775–9.PubMedCrossRef
14.
Paradinas PJ et al. A clinical, histopathologic and flow cytometric study of 149 complete moles, 146 partial moles, 107 non-molar hydropic abortions. Histopathology. 1996;28:101–9.PubMedCrossRef
15.
• Lertkhachonsuk A-a et al. Complete hydatidiform mole – change in clinical profile over three decades. J Reprod Med. 2012;57:470–4. Complete molar pregnancy is now diagnosed earlier at a university hospital in Bangkok, Thailand, leading to less presenting symptoms of vaginal bleeding and preeclampsia. However, risk for postmolar GTN has not been affected.
16.
Parazzini F et al. Parental age and risk of complete and partial hydatidiform mole. Br J Obstet Gynaecol. 1986;93:582–5.PubMedCrossRef
17.
Belfort P, Braga A. Changing in the clinical presentation of molar pregnancy. Rev Bras Ginecol Obstet. 2004;26:483–8.CrossRef
18.
Sebire NJ et al. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. Br J Obstet Gynaecol. 2002;109:99–102.CrossRef
19.
Altman AD et al. Maternal age-related rates of gestational trophoblastic disease. Obstet Gynecol. 2008;112:244–50.PubMedCrossRef
20.
Braga A et al. Molar pregnancy in adolescents. J Reprod Med. 2012;57:225–30.PubMed
21.
Parazzini F et al. Dietary factors and risk of trophoblastic disease. Am J Obstet Gynecol. 1988;158:93–100.PubMedCrossRef
22.
Elias K et al. Complete hydatidiform mole in women aged 40 to 49 years. J Reprod Med. 2012;57:254–8.PubMed
23.
Steller MA et al. Natural history of twin pregnancy with complete hydatidiform mole and co-existing fetus. Obstet Gynecol. 1994;83:35–42.PubMed
24.
Matsui H et al. Hydatidiform mole coexistent with a twin live fetus: a national collaborative study in Japan. Hum Reprod. 2000;15:608–11.PubMedCrossRef
25.
Sebire NJ et al. Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet. 2002;359:2165–6.PubMedCrossRef
26.
Kihara M et al. Complicating preeclampsia as a predictor of poor survival of the fetus in complete hydatidiform mole coexistent with twin fetus. J Reprod Med. 2012;57:325–8.PubMed
27.
Sebire NJ et al. Overdiagnosis of complete and partial mole in tubal ectopic pregnancies. Int J Gynecol Pathol. 2005;24:260–4.PubMedCrossRef
28.
Cortes-Charry R et al. Hydatidiform mole in ectopic pregnancy: clinical, imaging, pathological and immunohistochemical characteristics. J Reprod Med. 2012;57:329–32.PubMed
29.
Wolfberg AJ et al. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy. Obstet Gynecol. 2005;106:548–52.PubMedCrossRef
30.
Growdon W et al. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies. J Reprod Med. 2006;51:871–4.PubMed
31.
Kang WD, Choi HS, Kim SM. Prediction of persistent gestational trophoblastic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole. Gynecol Oncol. 2012;124:250–3.PubMedCrossRef
32.
FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynecol Obstet. 2002;77:285–7.CrossRef
33.
Cole LA, Butler S. Detection of hCG in trophoblastic disease: the USA hCG reference service experience. J Reprod Med. 2002;47:433–44.PubMed
34.
Cole LA, Khanlian A, Muller CY. Normal production of human chorionic gonadotropin in menopause. New Eng J Med. 2007;356:1184–6.PubMedCrossRef
35.
36.
Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia: a progress report. J Reprod Med. 2002;47:445–50.PubMed
37.
Lurain JR. Gestational trophoblastic disease. II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2010;203:11–8.CrossRef
38.
McGrath S et al. The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100,000 IU/L. Br J Cancer. 2010;102:810–4.PubMedCentralPubMedCrossRef
39.
Ross GT et al. Sequential use of methotrexate and actinomycin D in the treatment of metastatic choriocarcinoma and related trophoblastic tumors in women. Am J Obstet Gynecol. 1965;93:234–9.
40.
Chapman-Davis E et al. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single agent methotrexate chemotherapy. Gynecol Oncol. 2012;125:572–5.PubMedCrossRef
41.
Osathanondh R, Goldstein DP, Pastrofide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer. 1975;36:863–6.PubMedCrossRef
42.
Covens A et al. Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia. Cancer. 2006;107:1280–6.PubMedCrossRef
43.
Osborne RJ et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011;29:825–31.PubMedCrossRef
44.
Lurain JR et al. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia. J Reprod Med. 2012;57:283–7.PubMed
45.
Maesta I et al. Prognostic factors associated with time to hCG remission in patients with low-risk post-molar gestational trophoblastic neoplasia. Gynecol Oncol. 2013;130:312–6.PubMedCrossRef
46.
Shah NT et al. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. J Reprod Med. 2012;57:211–8.PubMed
47.
Rauh-Hain JA et al. Gestational trophoblastic neoplasia in adolescents. J Reprod Med. 2012;57:237–42.PubMed
48.
Cagayan MSFS. Vaginal metastases complicating gestational trophoblastic neoplasia. J Reprod Med. 2010;55:229–35.PubMed
49.
McGrath S et al. Embolization of uterine arteriovenous malformations in patients with gestational trophoblastic tumors. J Reprod Med. 2012;57:319–24.PubMed
50.
ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic neoplasms. Committee on Practise Bulletins-Gynecology. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2004;103:1365–73.
51.
• Lybol C et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;125:576–9. Little information is available to guide consolidation chemotherapy after achieving remission in GTN. This study indicates that 3 courses of consolidation chemotherapy is associated significantly with lower relapse rates than 2 courses in low-risk GTN.PubMedCrossRef
52.
Mapelli P et al. Role of 18 F-FDG-PET in the management of gestational trophoblastic disease. Eur J Nucl Med Mol Imaging. 2013;40:505–13.PubMedCrossRef
53.
Tomoda Y et al. Surgical indications for resection in pulmonary metastasis of choriocarcinoma. Cancer. 1980;46:2723–30.PubMedCrossRef
54.
Alfrangis C et al. Role of thoracotomy and metastasectomy in gestational trophoblastic neoplasia. A single center experience. J Reprod Med. 2012;57(7–8):350–8.
55.
Neubauer NL et al. Brain metastasis in gestational trophoblastic neoplasia. An update. J Reprod Med. 2012;57(7–8):288–92.PubMed
56.
Lurain JR et al. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med. 2012;57(5–6):219–24.PubMed
57.
Cagayan MSFS. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine) chemotherapy. J Reprod Med. 2012;57(5–6):231–6.PubMed
58.
Alazzam M, et al. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia (Review). The Cochrane Collaboration 2012, Issue 12.
59.
• Alfrangis C et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2012;31:280–6. Patients with high-risk GTN and large tumor burdens are at increased risk for early death. This study demonstrates that low-dose induction chemotherapy improves survival in these patients.CrossRef
60.
Hyman DM et al. Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome. Gynecol Oncol. 2013;129:58–62.PubMedCrossRef
61.
Kingdon SJ et al. Deaths from gestational trophoblastic neoplasia. Any Lessons to be learned? J Reprod Med. 2012;57(7–8):293–6.PubMed
Metadata
Title
Management Options of Gestational Trophoblastic Disease
Authors
Ross S. Berkowitz
Donald P. Goldstein
Neil S. Horowitz
Publication date
01-03-2014
Publisher
Springer US
Published in
Current Obstetrics and Gynecology Reports / Issue 1/2014
Electronic ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-013-0065-4

Other articles of this Issue 1/2014

Current Obstetrics and Gynecology Reports 1/2014 Go to the issue

Management of Gestational Trophoblastic Diseases (A Cheung, Section Editor)

Classification and Morphology of Gestational Trophoblastic Disease

Management of Gestational Trophoblastic Diseases (A Cheung, Section Editor)

Clinical Epidemiology of Gestational Trophoblastic Disease

Molecular Pathogenesis of Gynecologic Cancer (H Katabuchi and H Tashiro, Section Editors)

The Relationship Between Estrogen and Genes in the Molecular Pathogenesis of Endometrial Carcinoma

Management of Gestational Trophoblastic Diseases (A Cheung, Section Editor)

Management of Chemoresistant and Quiescent Gestational Trophoblastic Disease

Molecular Pathogenesis of Gynecologic Cancer (H Katabuchi and H Tashiro, Section Editors)

Molecular Pathogenesis of Uterine Serous Carcinoma

Management of Gestational Trophoblastic Diseases (A Cheung, Section Editor)

The hCG Group: the Key Molecules in Human Evolution, Human Life, and Human Death